Charles River Laboratories Intl. Inc vs Sirius XM Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Sirius XM Holdings Inc trades at $26.51 (market cap $8.87B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Sirius XM Holdings Inc for 102 Days on average.
| CRL | SIRI | |
|---|---|---|
Market Cap | $14.23B | $8.87B |
Volume | 1,176,885 | 4,324,672 |
Sector | Health | Media |
52-Week High | $310.77 | $32.59 |
52-Week Low | $149.93 | $19.92 |
Typical Hold Time | 33 Days | 102 Days |
Enterprise Value | $17.06B | $18.16B |
Dividend Yield | — | 4.1% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
Sirius XM Holdings (SIRI) trades at $26.33, up 1.46% on the day, with a neutral technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while profitability remains solid with a 10.23% net margin. Recent news highlights the company's YouTube partnership potential and strong cash flow growth, with institutional buying activity noted in September 2026.
The outlook is cautiously optimistic with a consensus price target of $34.43 suggesting 31% upside, though risks include competitive pressures in audio streaming and execution on new initiatives. The company's debt reduction and stable cash generation support the bullish analyst sentiment, but investors should weigh the recent earnings misses against growth initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →